Activiteiten per jaar
Samenvatting
The vast majority of preclinical studies of HDAC inhibitors (HDAC-I) focus on the drug-target (cancer) cell interaction, whereas little attention is paid to the effects on non-target healthy cells, which could provide decisive information to eliminate potential cytotoxic compounds at a very early stage during drug development. In the current study we used cultures of primary rat hepatocytes as a read out system to select for the most potent HDAC-I in the group of structural analogues of an archetypal HDAC-I, namely Trichostatin A. This kind of approach allowed selecting compounds with high biological activity and with no apparent toxicity towards cultured hepatocytes.
Originele taal-2 | English |
---|---|
Pagina's (van-tot) | 338-346 |
Aantal pagina's | 9 |
Tijdschrift | Invest New Drugs |
Volume | 27 |
Status | Published - 2009 |
Vingerafdruk
Duik in de onderzoeksthema's van 'Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors'. Samen vormen ze een unieke vingerafdruk.Activiteiten
-
Epigen meeting
Thierry Vandendriessche (Speaker)
27 feb 2014Activiteit: Talk or presentation at a workshop/seminar
-
-
Epigen meeting
Leo A Van Grunsven (Participant)
27 feb 2014Activiteit: Participation in workshop, seminar